The Pharma Data

The Pharma Data

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1 At 66…

Takeda Receives Approval to Manufacture and Market Entyvio® Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Entyvio® Pens for subcutaneous (SC) injection 108 mg / Syringes for SC injection 108 mg (generic name: vedolizumab (Genetical Recombination),…